Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBITDA Margin (2016 - 2025)

Integra Lifesciences Holdings' EBITDA Margin history spans 17 years, with the latest figure at 5.3% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 275.0% year-over-year to 5.3%; the TTM value through Dec 2025 reached 30.34%, down 3031.0%, while the annual FY2025 figure was 30.17%, 3194.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 5.3% at Integra Lifesciences Holdings, up from 1.61% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 21.06% in Q1 2021 and bottomed at 118.11% in Q2 2025.
  • The 5-year median for EBITDA Margin is 6.44% (2023), against an average of 0.65%.
  • The largest annual shift saw EBITDA Margin skyrocketed 2642bps in 2021 before it crashed -11321bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 14.36% in 2021, then increased by 19bps to 17.04% in 2022, then tumbled by -47bps to 9.08% in 2023, then fell by -11bps to 8.05% in 2024, then tumbled by -34bps to 5.3% in 2025.
  • Per Business Quant, the three most recent readings for IART's EBITDA Margin are 5.3% (Q4 2025), 1.61% (Q3 2025), and 118.11% (Q2 2025).